Sahu Jagdish K, Mishra Arun K
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, IFTM University, Moradabad - 244102, India.
Curr Drug Discov Technol. 2019;16(3):259-264. doi: 10.2174/1570163815666180502165014.
Ozenoxacin is one of the potent quinolone antibiotics, recently approved by the United States Food and Drug Administration (USFDA) with reported pharmacology to treat the impetigo. The demand for better acting topical formulation is increasing day by day. The present review is an attempt to summarize the facts behind the chemistry and biological applications of Ozenoxacin. Mechanism of Action: This novel drug being a quinolone antibiotic compound, acts by inhibiting DNA gyrase A and topoisomerase IV and affects supercoiling, supercoil relaxation, chromosomal condensation, chromosomal decatenation and many others. Pharmacology: Ozenoxacin has demonstrated to have a bactericidal activity against organisms, such as Staphylococcus aureus and Staphylococcus pyogenes. Ozenoxacin is non-fluorinated quinolone and being developed for the other dermatological bacterial infections as well. No sign of genotoxicity was observed when tested experimentally.
The present review also covers the complete picture of pharmacokinetics, clinical trials, toxicity and future scope and possible avenues in this arena.
奥泽沙星是一种强效喹诺酮类抗生素，最近获得美国食品药品监督管理局（USFDA）批准，据报道其药理学作用是治疗脓疱病。对作用更好的局部制剂的需求日益增加。本综述旨在总结奥泽沙星化学和生物学应用背后的事实。作用机制：这种新型药物作为喹诺酮类抗生素化合物，通过抑制DNA回旋酶A和拓扑异构酶IV起作用，并影响超螺旋、超螺旋松弛、染色体凝聚、染色体解连环等。药理学：奥泽沙星已证明对金黄色葡萄球菌和化脓性链球菌等生物体具有杀菌活性。奥泽沙星是一种非氟化喹诺酮类药物，也正在开发用于其他皮肤细菌感染。实验测试时未观察到遗传毒性迹象。
本综述还涵盖了该领域中药代动力学、临床试验、毒性以及未来前景和可能途径的全貌。
